Molecular characterization of lung adenocarcinoma: A potential four–long noncoding RNA prognostic signature

Sui, Jing; Yang, Sheng; Liu, Tong; Wu, Wenjuan; Xu, Siyi; Ye, Lihong; Pu, Yuepu; Zhang, Xiaomei; Zhang, Yan; Shen, Bo; Liang, Geyu

doi:10.1002/jcb.27428

Cited by 35 publications

(39 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 More recently, several panels of lncRNA biomarkers were found to have the capacity to predict the overall survival of patients with LUAD. [33][34][35] Nevertheless, lncRNA expression patterns and their prognostic value for relapse of earlystage LUAD remains to date unclear.…”

Section: Discussionmentioning

confidence: 99%

A seven‐long noncoding RNA signature predicts relapse in patients with early‐stage lung adenocarcinoma

Zhou

Zhang

Chen

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Background Long noncoding RNA (lncRNA) has been increasingly reported to play crucial roles in cancer development. In this study, we aim to develop a lncRNA‐based signature to predict the relapse of early‐stage (stage I‐II) lung adenocarcinoma (LUAD). Methods With a lncRNA‐mining strategy, lncRNA expression profiles of three LUAD cohorts were obtained from the Gene Expression Omnibus database. A risk score model was established based on the lncRNAs expression from training set (GSE31210, n = 204) and further validated in two independent testing sets (GSE50081, n = 124; and GSE30219, n = 84). The potential signaling pathways modulated by the prognostic lncRNAs were explored using bioinformatics analysis. Results In the training set, seven lncRNAs were identified to be significantly correlated with the relapse‐free survival (RFS) of early‐stage LUAD, and were then aggregated to form a seven‐lncRNA prognostic signature to classify patients into high‐risk and low‐risk groups. Individuals of training set in the high‐risk group exhibited a poorer RFS than those in the low‐risk group (HR: 7.574, 95% CI: 4.165‐13.775; P < 0.001). The similar prognostic powers of the seven‐lncRNA signature were also achieved in the two independent testing sets and in stratified analysis. Multivariate Cox regression indicated that the prognostic value of seven‐lncRNA signature was independent of other clinical features. Functional enrichment analysis found that the seven‐lncRNA signature may be involved in biological pathways such as cell cycle, DNA replication, and p53 signaling pathway. Conclusion Our results indicate that the seven‐lncRNA signature may be an innovative biomarker to predict the relapse of early‐stage LUAD.

show abstract

Section: Discussionmentioning

confidence: 99%

A seven‐long noncoding RNA signature predicts relapse in patients with early‐stage lung adenocarcinoma

Zhou

Zhang

Chen

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…Akt protein kinase B, CCND1 cyclin D1, CRC , colorectal cancer, E2F1, E2F transcription factor 1, EGFR epidermal growth factor receptor, EMT Epithelial-mesenchymal transition, ERK extracellular regulated protein kinases, ESCC esophageal squamous cell carcinoma, ETS1, ETS proto-oncogene 1, transcription factor, EZH2 enhancer of zeste 2 polycomb repressive complex 2 subunit, FIH-1 hypoxia inducible factor 1 subunit alpha inhibitor, FOXM1 forkhead box M1, GSK-3β glycogen synthase kinase-3β, HCC hepatocellular carcinoma, HIF-1α hypoxia inducible factor 1 subunit alpha, HNSCC head and neck squamous cell carcinoma, IFN-α/γ interferon-α/γ, LSCC laryngeal squamous cell cancer, LUAD lung adenocarcinoma, MMP1 matrix metallopeptidase 1, NSCLC Non-small cell lung cancer, NT5E 5′-nucleotidase ecto, OSCC oral squamous cell carcinoma, PDAC pancreatic ductal adenocarcinoma, PI3K phosphoinositide 3-kinase, RASA1 RAS p21 protein activator 1, RhoA ras homolog gene family, member A, ST7L suppression of tumorigenicity 7 like, TGF-β transforming growth factor-β, TNF tumor necrosis factor, VEGF vascular endothelial growth factor, VSCC vulvar squamous cell carcinoma Gastric cancer ↑ / p21, E-cadherin Cell proliferation, migration [33] Gastric cancer ↓ / E2F1 Cell proliferation [24] CRC ↑ / miR-31-5p, MYC, TNF-α/NF-κB, TGF-β, IFN-α/γ EMT [16] CRC ↓ / / Cell proliferation, apoptosis [18] HCC ↓ / miR-575, ST7L Cell proliferation, metastasis [5] Bladder cancer ↓ / / / [25] epithelial-mesenchymal transition (EMT) phenotype [2]. Jin et al identified that MIR31HG was induced by nuclear translocation of NF-κB, and in turn directly bind to IκBα and participated in NF-κB activation, revealing an interaction between MIR31HG and NF-κB in osteogenic differentiation [46].…”

Section: Table 3 Expression Pattern Of Mir31hg In Cancers and Its Intmentioning

confidence: 99%

“…Recently, an increasing number of studies have been exploring the prognostic association between MIR31HG and cancers. Abnormal expression of MIR31HG has been reported in a diverse range of cancer types, including osteosarcoma [15], chordoma [16], colorectal cancer (CRC) [17][18][19], hepatocellular carcinoma (HCC) [6], lung cancer [2,[20][21][22][23][24], gastric cancer [25], bladder cancer [26], pancreatic ductal adenocarcinoma (PDAC) [7], oral squamous cell carcinoma (OSCC) [4], breast cancer [13,27], cervical cancer [28], vulvar squamous cell carcinoma (VSCC) [29], and esophageal squamous cell carcinoma (ESCC) [30,31]. Furthermore, MIR31HG expression was remarkably associated with survival time, tumor-node metastasis (TNM) stage and carcinogenesis of certain cancers.…”

Section: Introductionmentioning

confidence: 99%

The predictive value of lncRNA MIR31HG expression on clinical outcomes in patients with solid malignant tumors

Ren

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background: Emerging studies have explored the prognostic value of MIR31HG in cancers, but its role remains elusive. Herein, we aimed to summarize the prognostic potential of MIR31HG in this study. Methods: Several databases were searched for literature retrieval on Dec 5, 2019. Overall and subgroup analyses were conducted to measure the relationship between MIR31HG expression and clinical outcomes. Moreover, GEPIA was applied for validation of prognostic value of MIR31HG in tumor patients in TCGA dataset. Results: Overall, seventeen studies with 2573 patients were enrolled. Compared to counterparts, those patients with high MIR31HG expression tended to have shorter RFS. Notably, MIR31HG overexpression predicted unfavorable OS in lung cancer. By contrast, gastrointestinal cancer patients with elevated MIR31HG expression predicted better OS and disease-free survival. Additionally, MIR31HG overexpression was significantly associated with worse clinicopathological features including advanced tumor stage and LNM in lung cancer, but favorable clinical characteristics in gastrointestinal cancer. Moreover, the positive association between MIR31HG and OS in lung cancer was further confirmed in TCGA dataset. Conclusion: Overexpression of MIR31HG suggested remarkable association with poor prognosis in terms of OS, tumor stage, and LNM in lung cancer, but favorable prognosis in gastrointestinal cancer. Therefore, MIR31HG may serve as a promising prognostic biomarker in multiple cancers.

show abstract

“…NSCLC contains lung adenocarcinoma (LUAD), large cell carcinoma (LCC) and lung squamous carcinoma (LUSC) subtypes . Also, in both main types of LC, carcinoid tumors can occur in the lungs that account for 1% to 2% of human lung tumors . In spite of significant advances in the treatment of LC, survival rates remain at 5 years because of the development of resistance to treatments .…”

Section: Introductionmentioning

confidence: 99%

Tumor suppressor microRNAs in lung cancer: An insight to signaling pathways and drug resistance

Asghariazar

Sakhinia

Mansoori

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Lung cancer (LC) is the second common cancer for both women and men all over the world. Unfortunately, the number of LC deaths is increasing rapidly each year so early diagnosis of LC can be lifesaving. MicroRNAs are involved in multiple processes, such as cell differentiation, transcription, inflammation, proliferation, cell signaling, and apoptosis. In LC, microRNAs function as tumor suppressors (TS) or oncogenes depending on the targets. Changes in microRNAs expression level are related to tumor initiation, progression, and metastasis. MicroRNAs can regulate gene expression and thus affect the activity status of different signaling pathways including AKT, JAK-STAT, MAPK, TGF-β, WNT, and ERK signaling pathways. Positive or negative effects on drug resistance of LC are directly affected by microRNAs and their target genes. MicroRNAs can be beneficial in combination therapy with other drugs and chemotherapeutic agents for LC. K E Y W O R D S drug resistance, lung cancer, microRNA, signaling pathways, tumor suppressor How to cite this article: Asghariazar V, Sakhinia E, Mansoori B, Mohammadi A, Baradaran B. Tumor suppressor microRNAs in lung cancer: An insight to signaling pathways and drug resistance.

show abstract

Molecular characterization of lung adenocarcinoma: A potential four–long noncoding RNA prognostic signature

Abstract: The four-lncRNA signature could become potential prognostic indicator of LUAD in the future.

Cited by 35 publications

References 43 publications

A seven‐long noncoding RNA signature predicts relapse in patients with early‐stage lung adenocarcinoma

A seven‐long noncoding RNA signature predicts relapse in patients with early‐stage lung adenocarcinoma

The predictive value of lncRNA MIR31HG expression on clinical outcomes in patients with solid malignant tumors

Tumor suppressor microRNAs in lung cancer: An insight to signaling pathways and drug resistance

Contact Info

Product

Resources

About